Intra-Cellular Therapies Inc. (ITCI) earnings
ITCI earnings moved a median of -0.01% by the close. Quarterly and annual ITCI reports and results, each read against the price at its own news timestamp. Back to the ITCI overview →
15 measured ITCI earnings events.
Where these ITCI earnings landedvs 15 measured ITCI earnings reactions
| Middle 50% of ITCI earnings reactions | -0.79% to +2.19% |
|---|---|
| Median reaction (to close) | -0.01% |
| Measured reactions | 15 |
Point-in-time · zero look-ahead
Half of the 15 ITCI earnings events with a measured close landed between -0.79% and +2.19%; 47% closed up.
| Date | Headline | Event | 5-min | To close |
|---|---|---|---|---|
| Form 10-K/A Intra-Cellular Therapies For: Dec 31 | SEC filing · Form 10-K | +0.04% | +0.08% | |
| Form 10-K Intra-Cellular Therapies For: Dec 31 | SEC filing · Form 10-K | -0.02% | -0.01% | |
| Form 10-Q Intra-Cellular Therapies For: Sep 30 | SEC filing · Form 10-Q | +7.11% | +8.34% | |
| Intra-Cellular Therapies Reports Third Quarter 2024 Financial Results, Provides Corporate Update and Raises 2024 Caplyta Sales Guidance | Press release | +7.11% | +8.34% | |
| Intra-Cellular Therapies to Host Third Quarter 2024 Financial Results Conference Call and Webcast | Press release | +0.16% | +2.90% | |
| Form 10-Q Intra-Cellular Therapies For: Jun 30 | SEC filing · Form 10-Q | -1.76% | -4.31% | |
| Intra-Cellular Therapies Reports Second Quarter 2024 Financial Results, Provides Corporate Update and Raises 2024 CAPLYTA Sales Guidance | Press release | -1.76% | -4.31% | |
| Intra-Cellular Therapies to Host Second Quarter 2024 Financial Results Conference Call and Webcast | Press release | -0.81% | -0.78% | |
| Form 10-Q Intra-Cellular Therapies For: Mar 31 | SEC filing · Form 10-Q | +0.22% | +2.14% | |
| Intra-Cellular Therapies Reports First Quarter 2024 Financial Results | Press release | +0.22% | +2.14% | |
| Intra-Cellular Therapies to Host First Quarter 2024 Financial Results Conference Call and Webcast | Press release | +0.03% | -0.88% | |
| Form 10-K Intra-Cellular Therapies For: Dec 31 | SEC filing · Form 10-K | -0.09% | +2.25% | |
| Form 10-Q Intra-Cellular Therapies For: Sep 30 | SEC filing · Form 10-Q | +1.68% | -0.74% | |
| Intra-Cellular Therapies Reports Third Quarter 2023 Financial Results and Raises 2023 CAPLYTA Sales Guidance | Press release | +1.68% | -0.74% | |
| Intra-Cellular Therapies to Host Third Quarter 2023 Financial Results Conference Call and Webcast | Press release | +0.57% | -0.81% |
Keep exploring
More ITCI: analyst actions → · SEC filings → · ITCI overview →
Other Healthcare names and their earnings
| Ticker | Events | Median 30-min | % positive |
|---|---|---|---|
| MELINTA THERAPEUTICS INC (MLNT) | 248 | -0.38% | 34% |
| Heron Therapeutics, Inc. (HRTX) | 247 | -0.34% | 42% |
| Avadel Pharmaceuticals plc - Ordinary Share (AVDL) | 246 | -0.16% | 42% |
| Cumberland Pharmaceuticals Inc. (CPIX) | 245 | 0.00% | 49% |
Same sector, same measurement: percent move vs. the price at the news timestamp, read at 30 minutes. Sample sizes differ, so the medians are comparable but the confidence behind them is not. These are each name’s all-news baseline, not its earnings — that is what the link opens.